Jean Bennett
Professor
Dpartment of Cell and Developmental Biology
Perelman School of Medicine, University of Pennsylvania;Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania;DNA, Tissue and Cell Line Bank for Retinal Degeneration, University of Pennsylvania;F. M. Kirby Center for Molecular Ophthalmology, University of Pennsylvania;Molecular Diagnostic Studies Unit for Patients with Retinal Degeneration, University of Pennsylvania
Follow
Claim
分享
Follow
Claim
分享
基本信息
views: 0
Career Trajectory
Bio
Jean Bennett studies the molecular genetics of inherited retinal degenerations with the idea of using this knowledge to develop rational approaches for treatment of these diseases. Target diseases include retinitis pigmentosa and age-related macular degeneration. Studies in her laboratory range from identifying the molecular bases of retinal degenerations, generating animal models for these diseases, evaluating novel vectors for retinal gene transfer, characterizing immune responses to gene transfer, developing novel gene-based approaches for reversal of sensory loss, and rescuing vision in animal models through gene based treatments. Dr. Bennett was one of the first investigators to use viral vectors to deliver transgenes to specific cells in the retina and also led the first team to demonstrate proof-of-principle of ocular gene therapy. She has developed a number of strategies for gene therapy-mediated treatments for retinal disease. Besides the eye, projects in Dr. Bennett's laboratory target other diseases/organs suffering from mutations in cilia proteins, including the ear (cochlea) and the kidney (renal tubular epithelium). Dr. Bennett's work leads naturally to translational research. For example, a study conducted in her lab and with collaborators at UPenn, Cornell and University of Florida led to a remarkable reversal of blindness in a canine model of a blinding disease affecting infants. This treatment is currently being tested in human clinical trials at several different Centers. Dr. Bennett is Scientific Director for the Phase I/II human clinical trial evaluating the safety and efficacy of gene transfer in Leber congenital amaurosis (LCA) due to RPE65 mutations. This trial is being carried out at The Children's Hospital of PHiladelphia (CHOP). This was the first study to report the exciting efficacy results in all twelve subjects, including 5 children.
Research Interests
Papers共 445 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Gene therapyno. 3-4 (2024): 175-186
Brain : a journal of neurology (2024)
Cold Spring Harbor Perspectives in Medicine (2024)
Current Research in Neurobiology (2023): 100089-100089
Silvia Cerolini,Jean Bennett,Bart Peter Leroy,Tomas S. Aleman,Avril Daly,Todd Durham, Courtney Coates, Mathew Pletcher,Sue Lacey
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCEno. 8 (2023)
Cited0Views0Bibtex
0
0
Cited0Views0Bibtex
0
0
OPHTHALMOLOGYno. 10 (2022): 1177-1191
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn